Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

DDP ip Combined With AG in PDAC With Peritoneal Metastasis

Phase 2

Conditions: Pancreatic Neoplasm

Interventions: Drug: intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel

First Posted Date: 2022-02-03

Last Posted Date: 2022-02-03

Lead Sponsor: Fudan University

Target Recruit Count: 44

Registration Number: NCT05222204

Locations: 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Prognostic Value of Sarcopenia and Nutritional Status in Early-stage Non-small Cell Lung Cancer

Not yet recruiting

Conditions: Sarcopenia
Non Small Cell Lung Cancer
Malnutrition

Interventions: Device: Inbody 570
Device: JAMAR Dynamometer
Radiation: CT scan

First Posted Date: 2022-01-28

Last Posted Date: 2022-01-28

Lead Sponsor: Fudan University

Target Recruit Count: 132

Registration Number: NCT05212285

Locations: 🇨🇳
Huadong hospital, Fudan University, Shanghai, Shanghai, China

Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer

Phase 2

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: Leuprolide acetate
Drug: Goserelin acetate
Drug: Triptorelin acetate
Drug: Degarelix acetate
Drug: Abiraterone acetate
Drug: Apalutamide
Drug: Enzalutamide
Procedure: Local treatment for primary lesion
Radiation: Radiotherapy for primary lesion
Radiation: Radiotherapy for metastatic lesion

First Posted Date: 2022-01-28

Last Posted Date: 2022-03-16

Lead Sponsor: Fudan University

Target Recruit Count: 160

Registration Number: NCT05212857

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02

Phase 2

Recruiting

Conditions: Breast Cancer
Metastatic Cancer

Interventions: Drug: Nab paclitaxel
Drug: SHR-1316
Drug: SHR6390
Drug: SERD
Drug: AI

First Posted Date: 2022-01-25

Last Posted Date: 2024-02-08

Lead Sponsor: Fudan University

Target Recruit Count: 338

Registration Number: NCT05205200

Locations: 🇨🇳
Fudan University Shanghai cancer center, Shanghai, China

Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer

Phase 3

Recruiting

Conditions: Rectal Cancer

Interventions: Drug: FOLFOXIRI
Drug: CapeOX

First Posted Date: 2022-01-21

Last Posted Date: 2022-03-04

Lead Sponsor: Fudan University

Target Recruit Count: 300

Registration Number: NCT05201430

Locations: 🇨🇳
Department of Colorectal Surgery Fudan University Shanghai Caner Center, Shanghai, Shanghai, China

Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer

Phase 2

Not yet recruiting

Conditions: Colorectal Neoplasms
Intestinal Neoplasms

Interventions: Drug: Camrelizumab
Drug: Trastuzumab
Drug: XELOX regimen
Drug: mFOLFOX6 regimen
Drug: FOLFIRI regimen
Drug: mXELIRI regimen
Drug: mIRIS regimen

First Posted Date: 2022-01-14

Last Posted Date: 2022-01-14

Lead Sponsor: Fudan University

Target Recruit Count: 77

Registration Number: NCT05193292

Locations: 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China

Circulating EV Long RNA Profiles in SCLC

Not Applicable

Recruiting

Conditions: Small Cell Lung Cancer

Interventions: Diagnostic Test: Blood sample collection

First Posted Date: 2022-01-14

Last Posted Date: 2022-01-14

Lead Sponsor: Fudan University

Target Recruit Count: 60

Registration Number: NCT05191849

Locations: 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China

The Effect of Intervention With Probiotic K56 on Body Fat Reduction in Obese Subjects

Not Applicable

Conditions: Obesity

Interventions: Dietary Supplement: Lactobacillus paracasei K56
Dietary Supplement: placebo

First Posted Date: 2022-01-14

Last Posted Date: 2022-01-14

Lead Sponsor: Fudan University

Target Recruit Count: 120

Registration Number: NCT05192811

Locations: 🇨🇳
Hua Dong Hospital Affiliated to Fu Dan University, Shanghai, China

Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial

Conditions: Prostate Cancer
Metastatic Disease
Castration-resistant Prostate Cancer

Interventions: Drug: Abiraterone
Drug: Prednisone
Drug: Androgen deprivation therapy

First Posted Date: 2022-01-12

Last Posted Date: 2022-01-12

Lead Sponsor: Fudan University

Target Recruit Count: 30

Registration Number: NCT05188911

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression

Phase 2

Active, not recruiting

Conditions: Diffuse Large B-cell Lymphoma(DLBCL)

Interventions: Drug: Zanubrutinib + R-CHOP

First Posted Date: 2022-01-12

Last Posted Date: 2024-05-17

Lead Sponsor: Fudan University

Target Recruit Count: 41

Registration Number: NCT05189197

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy